Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF

Marco Metra, Beth A. Davison, Claudio Gimpelewicz, Valentina Carubelli, G. Michael Felker, Gerasimos Filippatos, Barry H. Greenberg, Tsushung A. Hua, Zoe Liu, Peter Pang, Piotr Ponikowski, Thomas M. Severin, Adriaan A. Voors, Yi Wang, Gad Cotter, John R. Teerlink

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Site selection is critical in acute heart failure trials. We assessed whether the enrollment rate per site affects patients' characteristics, outcomes and treatment response. Methods and results A total of 1161 patients enrolled at 96 sites in the RELAX-AHF trial (serelaxin vs placebo) were included. Annualized enrollment rate was calculated as the total number of patients enrolled at each site divided by time that the site was open (patients per year). Sites were classified in low (< 10), medium (10–20) and high enrolling sites (> 20 patients per site/year) and were compared for prognosis and serelaxin effect. High enrolling sites were more prevalent in Eastern Europe and Israel. Time from hospital admission to randomization was shorter in high enrolling sites (6.3 ± 4.4 h > 20 patients sites versus 8.7 ± 4.5 h for < 10 patients sites; p < 0.0001). Patients had slightly fewer comorbidities, lower levels of natriuretic peptides and creatinine and more severe pulmonary congestion in high enrolling sites. Use of evidence-based therapies was higher in high enrolling sites. The rates of worsening heart failure to day 5, 180-day cardiovascular and all-cause mortality and 60-day heart failure/renal failure rehospitalization or cardiovascular death, were similar across study groups even after adjustment for covariates. The effects of serelaxin on these outcomes did not differ by enrollment rate. Conclusions Characteristics of RELAX-AHF study patients enrolled in high versus low enrolling sites differed only slightly and there were no differences in outcomes. Differences in serelaxin effects by enrollment rate were not discernible.

Original languageEnglish (US)
Pages (from-to)91-96
Number of pages6
JournalInternational Journal of Cardiology
Volume253
DOIs
StatePublished - Feb 15 2018

Fingerprint

Multicenter Studies
Outcome Assessment (Health Care)
Pharmaceutical Preparations
Heart Failure
Eastern Europe
Natriuretic Peptides
Israel
Random Allocation
Renal Insufficiency
Comorbidity
Creatinine
Placebos
Lung
Mortality

Keywords

  • Acute heart failure
  • Clinical trials
  • Prognosis
  • Site selection

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Metra, M., Davison, B. A., Gimpelewicz, C., Carubelli, V., Felker, G. M., Filippatos, G., ... Teerlink, J. R. (2018). Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. International Journal of Cardiology, 253, 91-96. https://doi.org/10.1016/j.ijcard.2017.09.185

Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. / Metra, Marco; Davison, Beth A.; Gimpelewicz, Claudio; Carubelli, Valentina; Felker, G. Michael; Filippatos, Gerasimos; Greenberg, Barry H.; Hua, Tsushung A.; Liu, Zoe; Pang, Peter; Ponikowski, Piotr; Severin, Thomas M.; Voors, Adriaan A.; Wang, Yi; Cotter, Gad; Teerlink, John R.

In: International Journal of Cardiology, Vol. 253, 15.02.2018, p. 91-96.

Research output: Contribution to journalArticle

Metra, M, Davison, BA, Gimpelewicz, C, Carubelli, V, Felker, GM, Filippatos, G, Greenberg, BH, Hua, TA, Liu, Z, Pang, P, Ponikowski, P, Severin, TM, Voors, AA, Wang, Y, Cotter, G & Teerlink, JR 2018, 'Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF', International Journal of Cardiology, vol. 253, pp. 91-96. https://doi.org/10.1016/j.ijcard.2017.09.185
Metra, Marco ; Davison, Beth A. ; Gimpelewicz, Claudio ; Carubelli, Valentina ; Felker, G. Michael ; Filippatos, Gerasimos ; Greenberg, Barry H. ; Hua, Tsushung A. ; Liu, Zoe ; Pang, Peter ; Ponikowski, Piotr ; Severin, Thomas M. ; Voors, Adriaan A. ; Wang, Yi ; Cotter, Gad ; Teerlink, John R. / Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. In: International Journal of Cardiology. 2018 ; Vol. 253. pp. 91-96.
@article{748f69fe65464144978a11c1e7e129f6,
title = "Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF",
abstract = "Background Site selection is critical in acute heart failure trials. We assessed whether the enrollment rate per site affects patients' characteristics, outcomes and treatment response. Methods and results A total of 1161 patients enrolled at 96 sites in the RELAX-AHF trial (serelaxin vs placebo) were included. Annualized enrollment rate was calculated as the total number of patients enrolled at each site divided by time that the site was open (patients per year). Sites were classified in low (< 10), medium (10–20) and high enrolling sites (> 20 patients per site/year) and were compared for prognosis and serelaxin effect. High enrolling sites were more prevalent in Eastern Europe and Israel. Time from hospital admission to randomization was shorter in high enrolling sites (6.3 ± 4.4 h > 20 patients sites versus 8.7 ± 4.5 h for < 10 patients sites; p < 0.0001). Patients had slightly fewer comorbidities, lower levels of natriuretic peptides and creatinine and more severe pulmonary congestion in high enrolling sites. Use of evidence-based therapies was higher in high enrolling sites. The rates of worsening heart failure to day 5, 180-day cardiovascular and all-cause mortality and 60-day heart failure/renal failure rehospitalization or cardiovascular death, were similar across study groups even after adjustment for covariates. The effects of serelaxin on these outcomes did not differ by enrollment rate. Conclusions Characteristics of RELAX-AHF study patients enrolled in high versus low enrolling sites differed only slightly and there were no differences in outcomes. Differences in serelaxin effects by enrollment rate were not discernible.",
keywords = "Acute heart failure, Clinical trials, Prognosis, Site selection",
author = "Marco Metra and Davison, {Beth A.} and Claudio Gimpelewicz and Valentina Carubelli and Felker, {G. Michael} and Gerasimos Filippatos and Greenberg, {Barry H.} and Hua, {Tsushung A.} and Zoe Liu and Peter Pang and Piotr Ponikowski and Severin, {Thomas M.} and Voors, {Adriaan A.} and Yi Wang and Gad Cotter and Teerlink, {John R.}",
year = "2018",
month = "2",
day = "15",
doi = "10.1016/j.ijcard.2017.09.185",
language = "English (US)",
volume = "253",
pages = "91--96",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF

AU - Metra, Marco

AU - Davison, Beth A.

AU - Gimpelewicz, Claudio

AU - Carubelli, Valentina

AU - Felker, G. Michael

AU - Filippatos, Gerasimos

AU - Greenberg, Barry H.

AU - Hua, Tsushung A.

AU - Liu, Zoe

AU - Pang, Peter

AU - Ponikowski, Piotr

AU - Severin, Thomas M.

AU - Voors, Adriaan A.

AU - Wang, Yi

AU - Cotter, Gad

AU - Teerlink, John R.

PY - 2018/2/15

Y1 - 2018/2/15

N2 - Background Site selection is critical in acute heart failure trials. We assessed whether the enrollment rate per site affects patients' characteristics, outcomes and treatment response. Methods and results A total of 1161 patients enrolled at 96 sites in the RELAX-AHF trial (serelaxin vs placebo) were included. Annualized enrollment rate was calculated as the total number of patients enrolled at each site divided by time that the site was open (patients per year). Sites were classified in low (< 10), medium (10–20) and high enrolling sites (> 20 patients per site/year) and were compared for prognosis and serelaxin effect. High enrolling sites were more prevalent in Eastern Europe and Israel. Time from hospital admission to randomization was shorter in high enrolling sites (6.3 ± 4.4 h > 20 patients sites versus 8.7 ± 4.5 h for < 10 patients sites; p < 0.0001). Patients had slightly fewer comorbidities, lower levels of natriuretic peptides and creatinine and more severe pulmonary congestion in high enrolling sites. Use of evidence-based therapies was higher in high enrolling sites. The rates of worsening heart failure to day 5, 180-day cardiovascular and all-cause mortality and 60-day heart failure/renal failure rehospitalization or cardiovascular death, were similar across study groups even after adjustment for covariates. The effects of serelaxin on these outcomes did not differ by enrollment rate. Conclusions Characteristics of RELAX-AHF study patients enrolled in high versus low enrolling sites differed only slightly and there were no differences in outcomes. Differences in serelaxin effects by enrollment rate were not discernible.

AB - Background Site selection is critical in acute heart failure trials. We assessed whether the enrollment rate per site affects patients' characteristics, outcomes and treatment response. Methods and results A total of 1161 patients enrolled at 96 sites in the RELAX-AHF trial (serelaxin vs placebo) were included. Annualized enrollment rate was calculated as the total number of patients enrolled at each site divided by time that the site was open (patients per year). Sites were classified in low (< 10), medium (10–20) and high enrolling sites (> 20 patients per site/year) and were compared for prognosis and serelaxin effect. High enrolling sites were more prevalent in Eastern Europe and Israel. Time from hospital admission to randomization was shorter in high enrolling sites (6.3 ± 4.4 h > 20 patients sites versus 8.7 ± 4.5 h for < 10 patients sites; p < 0.0001). Patients had slightly fewer comorbidities, lower levels of natriuretic peptides and creatinine and more severe pulmonary congestion in high enrolling sites. Use of evidence-based therapies was higher in high enrolling sites. The rates of worsening heart failure to day 5, 180-day cardiovascular and all-cause mortality and 60-day heart failure/renal failure rehospitalization or cardiovascular death, were similar across study groups even after adjustment for covariates. The effects of serelaxin on these outcomes did not differ by enrollment rate. Conclusions Characteristics of RELAX-AHF study patients enrolled in high versus low enrolling sites differed only slightly and there were no differences in outcomes. Differences in serelaxin effects by enrollment rate were not discernible.

KW - Acute heart failure

KW - Clinical trials

KW - Prognosis

KW - Site selection

UR - http://www.scopus.com/inward/record.url?scp=85040103960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040103960&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2017.09.185

DO - 10.1016/j.ijcard.2017.09.185

M3 - Article

VL - 253

SP - 91

EP - 96

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -